Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Sales of Investments

Cash received from selling or redeeming investments.

Abeona Therapeutics Inc.NASDAQ: ABEO

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $24.9M fell 54.1% year over year, behind the -9.4% change in trailing-twelve-month sales of investments. Sequentially, it fell 48.7% from the prior quarter. Over 3 fiscal years it compounded at +47.0% a year.

Context

  • Sales of investments amounted to 2874.1% of revenue in FY2025.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -54.1% toward the trailing-twelve-month pace of -9.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.9M-48.7% QoQ
Last fiscal yearDec 2025
$167.27M+39.2% YoY
LTMMar 2026
$137.91M-9.4% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.1%——
1 year+39.2%——
3-year CAGR+47.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
167.27M USD
Year-over-year change
+39.2%
4-year CAGR
+16.6%

Sales of Investments vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 sales of investments of $137.91M is the 5th largest of the 10 companies compared; the peer median is $109.4M.
  • Its year-over-year change of -9.4% is the 5th highest of 8, against a peer median of +8.4%.
  • Sales of investments amounts to 948.5% of revenue for ABEO, versus a peer median of 207.6%.
ABEO Competitors Peer median
Sales of Investments for ABEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$212M -16.7%+13.5%751.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$194.74M -49.2%+73.7%533.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$185.26M +87.4%——
ASMBAssembly Biosciences, Inc.LTM Mar 2026$147.6M +8.4%-0.1%207.6%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$137.91M -9.4%+47.0%948.5%
SGMTSagimet Biosciences Inc.LTM Mar 2026$109.4M +75.3%+127.7%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$85.26M +33.1%+56.1%37.5%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$34.02M -63.1%-38.6%15118.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
HUMAHumacyte, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding ABEO) $109.4M+8.4%+34.8%207.6%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
Deferred Income Tax00000
Stock-Based Compensation8.92M3.05M4.77M6.63M10.78M
Change in Working Capital(18.26M)(5.89M)(1.79M)(4.38M)(5.39M)
Accounts Receivables(3M)2.81M(2.04M)792K(5.06M)
Inventory0000(5.49M)
Accounts Payables(15.59M)(9.11M)2.04M(3.49M)6.54M
Other Working Capital324K404K(3.83M)(1.68M)(1.37M)
Other Non-Cash Items24.15M(5.52M)11M2.57M(156.46M)
Operating Cash Flow(65.67M)(43.48M)(37.01M)(56.02M)(76.33M)
Capital Expenditures(4.15M)(130K)(331K)(2.45M)(7.98M)
Acquisitions (Net)00000
Purchases of Investments(20.16M)(78.21M)(51.64M)(157.01M)(206.63M)
Sales of Investments90.38M52.64M51.97M120.2M167.27M
Other Investing Activities01.73M204K18K152.37M
Investing Cash Flow66.06M(23.96M)208K(39.24M)105.03M
Debt Repayment00020M0
Common Stock Issued24.03M46.96M37.39M85.63M26.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities831K(5K)(332K)(1.49M)(37K)
Financing Cash Flow24.86M43.17M37.06M104.14M26.04M
Effect of Forex Changes00000
Net Change in Cash25.26M(24.27M)256K8.88M54.74M
Free Cash Flow(69.82M)(43.61M)(37.34M)(58.46M)(84.3M)

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.